Upadacitinib for ulcerative colitis-Reference-Cited by-同舟云学术

Upadacitinib for ulcerative colitis

Published:2022-06 Issue:10341 Volume:399 Page:2077-2078
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ananthakrishnan Ashwin N

Publisher

Elsevier BV

Subject

General Medicine

Reference10 articles.

1. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials;Danese;Lancet,2022

2. Tofacitinib as induction and maintenance therapy for ulcerative colitis;Sandborn;N Engl J Med,2017

3. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis;Burr;Gut,2021

4. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis;Hanauer;Clin Gastroenterol Hepatol,2019

5. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis;Ytterberg;N Engl J Med,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Treatments, Emerging Therapeutics, and Natural Remedies for Inflammatory Bowel Disease;Molecules;2024-08-21

2. The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations;Expert Opinion on Biological Therapy;2024-08-02

3. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies;Cytokine & Growth Factor Reviews;2023-06

4. Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review;Biomedicines;2023-03-01

5. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis;Expert Review of Gastroenterology & Hepatology;2023-01-27